BackgroundWhile clinical experience with left ventricular assist devices (LVAD) continues to grow and evolve, little is known regarding the ongoing use of certain medications in this population. We sought to evaluate the utility of digoxin in LVAD recipients and its association with outcomes.MethodsA total of 505 patients who underwent continuous-flow LVAD implantation at 5 centers from 2007-2015 were included. Patients were divided into 4 groups: not on digoxin at any time (ND; n = 257), received digoxin pre implant (PreD; n = 144), received digoxin pre and post implant (ContD; n = 55), and received digoxin only post implant (PostD; n = 49). Survival and all-cause readmission were compared between the 4 groups.ResultsThere was no difference in survival at 1 year nor at 3 years between groups (ND = 88%, 66%, respectively; PreD = 85%, 66%; ContD = 86%, 57%; PostD = 90%, 51%; p = 0.7). Readmission per 100 days also was not different between groups (ND = 0.5, PreD = 0.6, ContD = 0.5, PostD = 0.7; p = 0.1).ConclusionsIn this large, multicenter cohort, use of digoxin was not associated with any significant benefit in regard to mortality or hospitalization in patients supported with a continuous-flow LVAD. Importantly, its discontinuation post implant did not worsen all-cause hospitalization or survival.
展开▼
机译：背景，随着左心室辅助装置（LVAD）的临床经验持续增长和发展，关于这种人群中某些药物的持续使用很少。我们试图评估Digoxin在LVAD受体中的效用及其与结果的关系。包括从2007 - 2015年的5个中心接受连续流动的LVAD植入的505名患者。患者分为4组：在任何时间（nd; n = 257），接受地氧蛋白前植入物（pred; n = 144），接受了Digoxin前后和植入后（Contd; n = 55），接受了Digoxin只有植入后（Postd; n = 49）。在4组之间比较生存和全部损失的再入院。结果在1年内存活率没有差异，或者分别在3年间（ND = 88％，66％; pred = 85％，66％;续= 86 ％，57％; Postd = 90％，51％; p = 0.7）。每100天的阅迟在组之间也没有差异（ND = 0.5，pred = 0.6，CONTD = 0.5，POSTD = 0.7; p = 0.1）。CONCLUSIONSINSINSINSINSINS，使用DIGOXIN的使用与任何显着益处无关关于患有连续流动LVAD的患者的死亡率或住院治疗。重要的是，它的停药后植入物并未恶化全部导致住院治疗或生存。
展开▼
